ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2020
Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC.
Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.The Lancet. Oncology · 2021Trial
- Is there a room for radical salvage resection in initially-unresectable non-small cell lung cancer patients after EGFR-TKI based therapy?Translational lung cancer research · 2026Article
- Clinical-radiomic model development for local recurrence prediction in stereotactic body radiation therapy-treated lung cancer: comparative analysis with radiobiological models.Scientific reports · 2026Article
- Commentary: Salvage Resection for Local Failure after Stereotactic Ablative Radiotherapy for Pulmonary Malignancies: A Retrospective, Single-Center Study.Journal of chest surgery · 2026Article
- Salvage Resection for Local Failure after Stereotactic Ablative Radiotherapy for Pulmonary Malignancies: A Retrospective, Single-Center Study.Journal of chest surgery · 2026Article
- Machine learning-based prognostic model for local control prediction in lung cancer patients undergoing stereotactic body radiation therapy: a preliminary study.European journal of medical research · 2026Article
- Comparison of surgery and stereotactic body radiation therapy for clinical stage I NSCLC: a propensity score-matched analysis from a single institution.Journal of thoracic disease · 2025Article
- Development and validation of a nomogram for local control prediction in lung cancer patients treated with stereotactic body radiation therapy based on clinical, dosimetric, and inflammation-related parameters.BMC pulmonary medicine · 2025Article
- Review
- Multimodality Management of Thoracic Tumors: Initial Experience With a Multidisciplinary Thoracic Ablation Conference.Annals of surgical oncology · 2024Article
- Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer.Journal of contemporary brachytherapy · 2024Article
- External validation of radiobiological models for local control prediction in lung cancer patients treated with stereotactic body radiation therapy.Frontiers in oncology · 2024Article
- Oligorecurrent Non-Small-Cell Lung Cancer Treated by Chemo-Radiation Followed by Immunotherapy and Intracranial Radiosurgery: A Case Report and Mini Review of Literature.International journal of molecular sciences · 2023Review
- Stereotactic body proton therapy for non-small cell lung cancer: Clinical indications and recommendations.Journal of radiosurgery and SBRT · 2023Article
- An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone".Radiation oncology (London, England) · 2022Article
- Review
- Developments in radiation techniques for thoracic malignancies.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence?Current oncology reports · 2021Review
- Machine Learning for the Prediction of Lymph Nodes Micrometastasis in Patients with Non-Small Cell Lung Cancer: A Comparative Analysis of Two Practical Prediction Models for Gross Target Volume Delineation.Cancer management and research · 2021Article
- Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC.JTO clinical and research reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 5 countries.
Funding
Abstract
Although isolated local (LRs) and regional recurrences (RRs) constitute a minority of post-stereotactic ablative radiotherapy (SABR) relapses, their management is becoming increasingly important as the use of SABR continues to expand. However, few evidence-based strategies are available to guide treatment of these potentially curable recurrences. On behalf of the Advanced Radiation Technology Committee of the International Association for the Study of Lung Cancer, this article was written to address management of recurrent disease. Topics discussed include diagnosis and workup, including the roles of volumetric and functional imaging as well as histopathologic methods; clinical outcomes after salvage therapy; patterns of recurrence after salvage therapy; and management options. Our main conclusions are that survival for patients with adequately salvaged LRs is similar to that for patients after primary SABR without recurrence, and survival for those with salvaged RRs (regardless of nodal burden or location) is similar to that of patients with de novo stage III disease. Although more than half of patients who undergo salvage do not develop a second relapse, the predominant pattern of second failure is distant, especially for RRs. Management requires rigorous multidisciplinary coordination. Isolated LRs can be managed with resection and nodal dissection, repeat SABR, thermal ablation, or systemic therapies. RRs can be treated with combined chemoradiotherapy, radiation or chemotherapy alone, or supportive services. Finally, regular and structured follow-up is recommended after post-SABR salvage therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.